Table 3.
Recent Studies Presenting Different Liposome-Based Bioformulations for Drug Delivery in LC Treatment
| Liposome | Drug | Formulation Name | In vitro or in vivo/Model | Cancer Type | Result | References |
|---|---|---|---|---|---|---|
| Liposome | Doxorubicin (Dox) | SA-5-Dox-LP | In vivo/mice with lung tumors In vitro/BT-474, A549, Calu-3, and MCF-7 cells |
NSCLC | Targeted SA-5-Dox-LP showed better anti-proliferative activity | [94] |
| Chitosan oligosaccharide-modified liposomes | Paclitaxel (PTX) | PTX-loaded CP50-LSs | In vitro/A549 In vivo/mice |
LC | CSO modification provides promising applicability for nanomedicine | [95] |
| RGD-modified liposomes | DOX | DOX-RGD-LPs | In vitro/A549 In vivo/Balb/c nude mice |
LC | The DOX-loaded pH-sensitive liposome, which has been modified with 5% cRGD-lipid, could be used to enhance cancer therapy | [96] |
| Liposome | Lonidamine or Epirubicin | - | In vitro/A549 cells In vivo/Female BALB/c mice |
NSCLC | The formulation used as an anticancer agent to treat drug-resistant LC | [97] |
| Folate-modified submicron-sized liposome (ssLip) | Rapamycin (RM) | RM/FA-ssLip | In vitro/KB and LL2 cells and A549 cells In vivo/Male C57BL/6NCr mice |
LC | Administration of this formulation extended the survival of LL2 cell tumor-bearing mice | [98] |
| pH-sensitive liposomes (PSL) | Thymoquinone (TQ) | TQPSL | In vivo/Swiss Albino Mice | LC | It shows potential of TQPSL as a LC therapeutic agent | [99] |
| PEGylated liposome | Lycobetaine Olic acid RGD |
LBT-OA-PEG-Lipo + nRGD | In vivo/ mice xenograft | Lung carcinoma | Improved tumor penetration, and increased extravasation of formulations and antitumor efficacy | [93] |
| PSL | Afatinib (tyrosine kinase inhibitor) | AFT loaded PSL | In vitro/human LC cells (H-1975) | NSCLC cells | AFT loaded-PSL prompted apoptosis in H-1975 cells | [100] |
| Liposome | Betulinic parthenolide, honokiol and ginsenoside Rh2 | Drug-loaded liposome | In vivo/mice In vitro/A549 cells |
LC | Cocktail liposome systems could offer a more efficient and safer treatment for LC | [101] |
| PEGylated cationic liposomes | PTX | MLV-PEG-PTX | In vivo/Female C57BL/6 mice In vitro/A549 and the murine lung carcinoma cell line LL/2 |
LC | MLV-PEG-PTX exhibited biocompatibility and anticancer activity against CSCs | [53] |
| DSPE-PEG2000-PFV | Daunorubicin and Dioscin | Daunorubicin and dioscin co-delivery liposomes | In vitro/A549 cells In vivo/Male BALB/c nude mice |
NSCLC | Increased the cellular uptake facilitated by PFV cell-penetrating peptide; augmented inhibitory effects on vasculogenic mimicry formation and tumor metastasis from the inclusion of dioscin | [102] |
| Liposome | Docetaxel and CD133 aptamers | CD133-DTX LP | In vitro/A549 tumor mice In vivo/mice xenograft |
LC | CD133-DTX LP significantly decreased cell proliferation and improved the therapeutic efficiency | [103] |
| Folate-modified liposomes | Metallothionein 1D pseudogene (MT1DP) Erastin |
Erastin/MT1DP@FA-LPs (E/M@FA-LPs) | In vitro/A549 and H1299 cells In vivo/BALB/c nude mice |
NSCLS | The combination increased the bioavailability and effectiveness of the drug/gene | [104] |
| Folate-modified liposome (F-PLP) | Plasmid BIM | F-PLP/pBIM | In vitro/LL/2 and A549 LC In vivo/Female C57BL/6 mice |
NSCLS | Developed formulation considerably blocked tumor growth by inducing apoptosis in tumor cells, and inhibited proliferation and angiogenesis | [105] |
| Liposome | Curcumin | Liposomal curcumin dry powder inhaler (LCD) | In vitro/A549 cells | Primary LC | Formulation having notable anticancer effects compared with the other two medications with reference to the pathology | [90] |
| Liposome | Inhalable Pirfenidone (PFD) | PFD-loaded liposomes | In vitro/H4006, A549 cell lines | NSCLC | PFD-loaded liposomes induced cell migration, apoptosis, and angiogenesis assays | [92] |
| Cationic liposome | PTX and Survivin siRNA | L-PTX-PSur | In vitro/NCI-H460 LC cells | LC | Developed formulation synergistically inhibits cancer cell growth | [106] |
| Liposome | PTX Curcumin (CUR) RGD |
RGD- PTX-CUR LPs | In vitro/A549 LC cell lines In vivo/BALB/c nude mice |
LC | The present formulation shows the antitumor effect in vivo, compared with the non-modified LPs | [52] |
| Liposome | PTX | LP (liposomal paclitaxel)-in-E. coli (LPE) | In vitro/A549 LC cell lines | LC | LPE significantly down-regulated the VEGF and HIF-1α in rat primary LC, and exacerbated apoptosis in the same cells | [107] |